Clinical Trials at UW Health Carbone Cancer Center Rockford
As of August 2026, 25 paid clinical trials are recruiting at UW Health Carbone Cancer Center Rockford in Rockford, Illinois. Active studies at this site cover conditions such as Anatomic Stage II Breast Cancer AJCC v8, Advanced Esophageal Adenocarcinoma and Advanced Gastric Adenocarcinoma. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
25 clinical trials at UW Health Carbone Cancer Center Rockford
·Clear filters·Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Common conditions studied in Rockford
- Anatomic Stage II Breast Cancer AJCC v8 (4 active studies)
- Advanced Esophageal Adenocarcinoma (2 active studies)
- Advanced Gastric Adenocarcinoma (2 active studies)
- Advanced Gastroesophageal Junction Adenocarcinoma (2 active studies)
- Anatomic Stage I Breast Cancer AJCC v8 (2 active studies)
- Anatomic Stage III Breast Cancer AJCC v8 (2 active studies)
Leading research sponsors in Rockford
- National Cancer Institute (NCI)
- Alliance for Clinical Trials in Oncology
- NRG Oncology
- SWOG Cancer Research Network
- AstraZeneca
Frequently asked questions
How many paid clinical trials are currently recruiting in Rockford?
There are approximately 54 recruiting clinical trials in Rockford, Illinois listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Rockford pay participants?
Most recruiting trials in Rockford compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Rockford?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Rockford?
The most common conditions under active study in Rockford include Anatomic Stage II Breast Cancer AJCC v8 (4), Advanced Esophageal Adenocarcinoma (2), Advanced Gastric Adenocarcinoma (2), Advanced Gastroesophageal Junction Adenocarcinoma (2), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Rockford?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Rockford on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Rockford?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Rockford?
Recruiting research sites in Rockford include UW Health Carbone Cancer Center Rockford, OSF Saint Anthony Medical Center, Mercyhealth Cancer Institute - Rockford, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Rockford right now?
The largest active categories in Rockford are Cancer & tumors (35), Mental health & behavior (3), Cardiovascular (3). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.